New Parkinson’s Treatment Solengepras Enters Phase 3 Testing

A promising new treatment for Parkinson’s disease, called solengepras, has started its final phase of testing in a large-scale clinical trial. The trial, named ARISE, is evaluating how well this new medication works when combined with traditional Parkinson’s treatments, like levodopa. Why This Matters Parkinson’s disease happens when certain brain cells that produce dopamine—a chemical that helps control movement—start to die off. While levodopa is the main treatment, long-term use can lead to side effects like dyskinesia (uncontrolled movements) and “off” periods, where symptoms aren’t managed well. Researchers are looking for therapies to improve symptom control while reducing these problems. What is Solengepras? Solengepras, also known as CVN424, is a small molecule drug designed to work differently from current Parkinson’s treatments. Instead of directly increasing dopamine levels, it targets a brain receptor called GPR6, found in areas that control movement. By blocking this receptor, solengepras aims to mimic the positive effects of levodopa without causing as many side effects. In earlier studies, solengepras helped reduce “off” times (when symptoms return) and increased “on” times (when symptoms are well managed) for Parkinson’s patients. It was also well tolerated, with no serious side effects reported. About the Phase 3 ARISE Trial The ARISE trial will include 330 participants, all of whom are already taking levodopa but experience at least three hours of “off” time daily. Participants will receive either a low or high dose of solengepras (75 or 150 mg) or a placebo, once daily for 12 weeks. The trial’s main focus is to see if solengepras reduces “off” time. Other goals include measuring improvements in controlled movement (“on” time without dyskinesia), overall symptom severity, and quality of life. Participants who complete the trial will have the option to join a follow-up study, where everyone will receive solengepras. What’s Next? If this Phase 3 trial is successful, solengepras could become an important new option for Parkinson’s patients, offering better symptom control with fewer side effects. Cerevance, the company behind solengepras, expects to have results by mid-2026. This new therapy is also being tested on its own (without levodopa) in another clinical trial for people with early-stage Parkinson’s who haven’t yet started treatment. A Step Forward for Parkinson’s Care “This is an exciting moment in Parkinson’s research,” said Sagar Vaidya, MD, PhD, Chief Medical Officer at Cerevance. “We hope solengepras will provide better symptom control and fewer motor complications for those living with Parkinson’s.” The Parkinson’s community awaits these developments with optimism, as new treatments like solengepras could improve the daily lives of millions.